Jane Levesley1, Lynette Steele1, Anke Brüning-Richardson1, Adam Davison2, Jia Zhou3, Chunyong Ding3, Sean Lawler4, Susan C Short1. 1. Translational Neuro-Oncology Group, Leeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK. 2. Flow Cytometry Facility, Leeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK. 3. Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA. 4. Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
Background: CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-cell lymphoma 2 (BCL-2) family inhibitors may enhance tumor cell killing when combined with conventional and targeted chemotherapeutic agents. We investigated the effect of disrupting BCL-2 and B cell lymphoma-extra large (BCL-XL) protein function using ABT-263, ABT-199 and WEHI-539 in medulloblastoma and pGBM cells following treatment with MLN8237, an Aurora kinase inhibitor under investigation as a novel agent for the treatment of malignant brain tumors. Methods: Tumor cell growth and viability were determined by MTT/WST-1 assays and flow cytometry. Effects on cell phenotype, cell cycle progression, and ploidy were determined by live cell imaging and DNA content analysis. Apoptosis was determined by annexin V/propidium iodide staining and time-lapse microscopy and confirmed by measuring caspase-3/7 activity and western blotting and by short interfering RNA (siRNA) knockdown of BCL-2 associated X protein/BCL-2 antagonist killer (BAX/BAK). Results: ABT-263, in combination with MLN8237, reduced mitotic slippage and polyploidy and promoted the elimination of mitotically defective cells via a BAX/BAK-dependent, caspase-mediated apoptotic pathway. The BCL-XL antagonist, WEHI-539, significantly augmented tumor cell killing when used in combination with MLN8237, as well as sensitized resistant brain tumor cells to a novel BAX activator, SMBA1. In addition, siRNA-mediated knockdown of BCL-XL sensitized pGBM and medulloblastoma cells to MLN8237 and mimicked the effect of combination drug treatment. Conclusion: Selective small-molecule inhibitors of BCL-XL may enhance the efficacy of MLN8237 and other targeted chemotherapeutic agents.
Background: CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-cell lymphoma 2 (BCL-2) family inhibitors may enhance tumor cell killing when combined with conventional and targeted chemotherapeutic agents. We investigated the effect of disrupting BCL-2 and B cell lymphoma-extra large (BCL-XL) protein function using ABT-263, ABT-199 and WEHI-539 in medulloblastoma and pGBM cells following treatment with MLN8237, an Aurora kinase inhibitor under investigation as a novel agent for the treatment of malignant brain tumors. Methods:Tumor cell growth and viability were determined by MTT/WST-1 assays and flow cytometry. Effects on cell phenotype, cell cycle progression, and ploidy were determined by live cell imaging and DNA content analysis. Apoptosis was determined by annexin V/propidium iodide staining and time-lapse microscopy and confirmed by measuring caspase-3/7 activity and western blotting and by short interfering RNA (siRNA) knockdown of BCL-2 associated X protein/BCL-2 antagonist killer (BAX/BAK). Results:ABT-263, in combination with MLN8237, reduced mitotic slippage and polyploidy and promoted the elimination of mitotically defective cells via a BAX/BAK-dependent, caspase-mediated apoptotic pathway. The BCL-XL antagonist, WEHI-539, significantly augmented tumor cell killing when used in combination with MLN8237, as well as sensitized resistant brain tumor cells to a novel BAX activator, SMBA1. In addition, siRNA-mediated knockdown of BCL-XL sensitized pGBM and medulloblastoma cells to MLN8237 and mimicked the effect of combination drug treatment. Conclusion: Selective small-molecule inhibitors of BCL-XL may enhance the efficacy of MLN8237 and other targeted chemotherapeutic agents.
Authors: Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson Journal: Cell Cycle Date: 2012-02-01 Impact factor: 4.534
Authors: Joanna Triscott; Cathy Lee; Colleen Foster; Branavan Manoranjan; Mary Rose Pambid; Rachel Berns; Abbas Fotovati; Chitra Venugopal; Katrina O'Halloran; Aru Narendran; Cynthia Hawkins; Vijay Ramaswamy; Eric Bouffet; Michael D Taylor; Ash Singhal; Juliette Hukin; Rod Rassekh; Stephen Yip; Paul Northcott; Sheila K Singh; Christopher Dunham; Sandra E Dunn Journal: Cancer Res Date: 2013-09-09 Impact factor: 12.701
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Yael P Mossé; Emily Lipsitz; Elizabeth Fox; David T Teachey; John M Maris; Brenda Weigel; Peter C Adamson; Mark A Ingle; Charlotte H Ahern; Susan M Blaney Journal: Clin Cancer Res Date: 2012-09-17 Impact factor: 12.531
Authors: Daniel Westaby; Juan M Jimenez-Vacas; Ana Padilha; Andreas Varkaris; Steven P Balk; Johann S de Bono; Adam Sharp Journal: Cancers (Basel) Date: 2021-12-23 Impact factor: 6.639
Authors: Anke Brüning-Richardson; Gary C Shaw; Daniel Tams; Tim Brend; Hitesh Sanganee; Simon T Barry; Gregory Hamm; Richard J A Goodwin; John G Swales; Henry King; Lynette Steele; Ruth Morton; Anastasia Widyadari; Thomas A Ward; Filomena Esteves; Marjorie Boissinot; Georgia Mavria; Alastair Droop; Sean E Lawler; Susan C Short Journal: Cancers (Basel) Date: 2021-11-25 Impact factor: 6.575
Authors: Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang Journal: Med Res Rev Date: 2020-11-06 Impact factor: 12.944